Moreover, PDGFRB rather than FGFR2 could form a heterodimer with EGFR on bladder cancer cells, and this could induce resistance to anti-EGFR therapy for bladder cancer[14]. This evidence concerns the gene FGFR2 and urinary bladder carcinoma.